PDEX Quote, Financials, Valuation and Earnings

InfuSystems Holdings has a net margin of 16.56% compared to Pro-Dex's net margin of 5.12%. Pro-Dex's return on equity of 16.73% beat InfuSystems Holdings's return on equity of 2.8%.

Pro-Dex has a consensus price target of --, signalling upside risk potential of 6.84%. On the other hand InfuSystems Holdings has an analysts' consensus of -- which suggests that it could grow by 69.98%. Given that InfuSystems Holdings has higher upside potential than Pro-Dex, analysts believe InfuSystems Holdings is more attractive than Pro-Dex.

Pro-Dex has a beta of 0.559, which suggesting that the stock is 44.102% less volatile than S&P 500. In comparison InfuSystems Holdings has a beta of 1.528, suggesting its more volatile than the S&P 500 by 52.819%.

Pro-Dex has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InfuSystems Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pro-Dex pays -- of its earnings as a dividend. InfuSystems Holdings pays out -- of its earnings as a dividend.

Pro-Dex quarterly revenues are $14.9M, which are smaller than InfuSystems Holdings quarterly revenues of $35.3M. Pro-Dex's net income of $2.5M is higher than InfuSystems Holdings's net income of $1.8M. Notably, Pro-Dex's price-to-earnings ratio is 31.81x while InfuSystems Holdings's PE ratio is 131.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pro-Dex is 2.98x versus 1.35x for InfuSystems Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Retractable Technologies has a net margin of 16.56% compared to Pro-Dex's net margin of -18.58%. Pro-Dex's return on equity of 16.73% beat Retractable Technologies's return on equity of -16.83%.

Pro-Dex has a consensus price target of --, signalling upside risk potential of 6.84%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that Pro-Dex has higher upside potential than Retractable Technologies, analysts believe Pro-Dex is more attractive than Retractable Technologies.

Pro-Dex has a beta of 0.559, which suggesting that the stock is 44.102% less volatile than S&P 500. In comparison Retractable Technologies has a beta of 1.979, suggesting its more volatile than the S&P 500 by 97.877%.

Pro-Dex has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pro-Dex pays -- of its earnings as a dividend. Retractable Technologies pays out -3.32% of its earnings as a dividend.

Pro-Dex quarterly revenues are $14.9M, which are larger than Retractable Technologies quarterly revenues of $10.3M. Pro-Dex's net income of $2.5M is higher than Retractable Technologies's net income of -$1.9M. Notably, Pro-Dex's price-to-earnings ratio is 31.81x while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pro-Dex is 2.98x versus 0.50x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Catheter Precision has a net margin of 16.56% compared to Pro-Dex's net margin of -4291.67%. Pro-Dex's return on equity of 16.73% beat Catheter Precision's return on equity of -65.84%.

Pro-Dex has a consensus price target of --, signalling upside risk potential of 6.84%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 506.06%. Given that Catheter Precision has higher upside potential than Pro-Dex, analysts believe Catheter Precision is more attractive than Pro-Dex.

Pro-Dex has a beta of 0.559, which suggesting that the stock is 44.102% less volatile than S&P 500. In comparison Catheter Precision has a beta of -0.210, suggesting its less volatile than the S&P 500 by 121.025%.

Pro-Dex has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pro-Dex pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

Pro-Dex quarterly revenues are $14.9M, which are larger than Catheter Precision quarterly revenues of $96K. Pro-Dex's net income of $2.5M is higher than Catheter Precision's net income of -$4.1M. Notably, Pro-Dex's price-to-earnings ratio is 31.81x while Catheter Precision's PE ratio is 0.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pro-Dex is 2.98x versus 0.88x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of 16.56% compared to Pro-Dex's net margin of -17.98%. Pro-Dex's return on equity of 16.73% beat Xtant Medical Holdings's return on equity of -35.98%.

Pro-Dex has a consensus price target of --, signalling upside risk potential of 6.84%. On the other hand Xtant Medical Holdings has an analysts' consensus of -- which suggests that it could grow by 525%. Given that Xtant Medical Holdings has higher upside potential than Pro-Dex, analysts believe Xtant Medical Holdings is more attractive than Pro-Dex.

Pro-Dex has a beta of 0.559, which suggesting that the stock is 44.102% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.342%.

Pro-Dex has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pro-Dex pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Pro-Dex quarterly revenues are $14.9M, which are smaller than Xtant Medical Holdings quarterly revenues of $27.9M. Pro-Dex's net income of $2.5M is higher than Xtant Medical Holdings's net income of -$5M. Notably, Pro-Dex's price-to-earnings ratio is 31.81x while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pro-Dex is 2.98x versus 0.42x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.